Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
heat-killed lactobacillus salivarius subsp. salicinius AP-32
- Development stage
- Preclinical
- Lead developer
- Glac Biotech
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Heat-killed Lactobacillus salivarius subsp. salicinius AP-32 is a postbiotic therapeutic developed by Bioflag Biotech. The active ingredient is the heat-inactivated bacterial strain *L. salivarius* subsp. *salicinius* AP-32, which was originally isolated from the healthy human gut. This biologic is formulated as oral tablets or lozenges for oral health applications. Its mechanism involves modulating the oral microbiome and local immunity by increasing salivary IgA concentration through IL-10 and TGF-beta mediated immune responses. This action helps to inhibit oral pathogens such as *Streptococcus mutans*, *Porphyromonas gingivalis*, and *Fusobacterium nucleatum*, and it has also shown activity against *Helicobacter pylori*. As a heat-killed preparation, it offers advantages over live probiotics, including enhanced stability and an improved safety profile.
02
Targets
NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)IL10 (Interleukin-10)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on heat-killed lactobacillus salivarius subsp. salicinius AP-32.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on heat-killed lactobacillus salivarius subsp. salicinius AP-32.